Last reviewed · How we verify
NECVAX-NEO1
At a glance
| Generic name | NECVAX-NEO1 |
|---|---|
| Also known as | Personalised neoantigen-targeting oral DNA cancer vaccine |
| Sponsor | NEC Bio B.V |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer (PHASE1, PHASE2)
- Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors (PHASE1, PHASE2)
- NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NECVAX-NEO1 CI brief — competitive landscape report
- NECVAX-NEO1 updates RSS · CI watch RSS
- NEC Bio B.V portfolio CI